MELANOMA

This study tested whether combining two existing cancer drugs, brentuximab vedotin and pembrolizumab, could help treat several types of advanced cancer that had spread to other parts of the body. It involved 161 people with metastatic melanoma, non-small cell lung cancer, or head…

This study tested whether adding a bone-strengthening drug (denosumab) to a standard immunotherapy could improve the body's ability to fight advanced melanoma. It involved 25 adults with stage III or IV melanoma who had not yet received certain immunotherapies. Researchers took b…

This early-stage study tested a new, personalized vaccine for people with advanced melanoma that had spread. Doctors created the vaccine for each patient using proteins from their own tumor cells, combined with immune-boosting agents, and placed it under the skin in a small, diss…

This early-stage study tested whether adding a new investigational therapy called VE800—a preparation of specific bacteria—could improve the effectiveness of an existing immunotherapy drug (nivolumab) in patients with advanced or metastatic cancers. The trial enrolled 56 patients…

This study tested two different doses of an experimental immunotherapy drug called RO7247669 in people with advanced melanoma that cannot be removed by surgery. The goal was to see how well the drug works, how safe it is, and to pick the best dose for future research. The trial i…

This early-stage study tested whether a patient's own immune cells could be genetically modified in a lab to recognize and attack cancer cells, then safely given back to the patient. It involved 10 adults with specific types of bladder, skin (melanoma), or head and neck cancers w…

This study tested a two-part immunotherapy for people with advanced melanoma that could still be removed by surgery. The goal was to see if giving a new drug (Tavo) injected directly into the tumor, along with a standard immunotherapy (nivolumab) given by IV, before surgery could…

This study tested a new drug, CFT1946, for people with advanced solid tumors that have a specific genetic change called BRAF V600. The main goals were to find a safe dose and see if the drug, given alone or with other medications, could help control the cancer. It involved 89 adu…

This study tested new drug combinations for people with melanoma skin cancer that had spread to the brain. The goal was to find treatments that are safer and work better than current options. It involved 56 participants and measured how well the tumors shrank and how long the res…

This study tested a personalized cell therapy for people with advanced melanoma that had stopped responding to standard treatments. Doctors took immune cells from a patient's own tumor, grew large numbers of them in a lab, and then infused them back into the patient. The main goa…

This early-stage study tested a new two-part treatment for advanced melanoma that cannot be surgically removed. The treatment involved injecting a modified virus directly into tumors to deliver a gene that may help the immune system fight cancer, combined with an oral pill to act…

This large, completed Phase 3 trial tested whether a new two-drug combination (LGX818 + MEK162) could better control advanced melanoma with a specific BRAF gene mutation. It compared the combo against a standard single-drug treatment (vemurafenib) and against one of the new drugs…

This study tested six different drug combinations in people with Stage III melanoma who were scheduled for surgery. The goal was to see if adding new experimental drugs to a standard immunotherapy (pembrolizumab) could shrink tumors more effectively and safely before the operatio…

This study observed 39 patients in Turkey with high-risk melanoma who had surgery to remove their cancer. Doctors then gave them a two-drug combination (dabrafenib and trametinib) to try to prevent the cancer from coming back. The main goal was to see how long patients stayed can…

This early-stage study tested an investigational drug called PLX3397 in a small group of adults with advanced melanoma that had spread and could not be surgically removed. The cancer also had to have a specific genetic change called a KIT mutation. The main goals were to check th…

This study aimed to find the best length of immunotherapy treatment for people with advanced cancers. It enrolled 161 patients whose cancer had remained stable after one year of treatment. Researchers randomly assigned participants to either stop their immunotherapy or continue i…

This early-stage study tested the safety and initial effectiveness of combining two existing cancer drugs, trametinib and ceritinib, in patients with advanced melanoma that could not be surgically removed. It involved 27 patients whose cancer had worsened despite previous standar…

This early-stage study tested a new, personalized vaccine for melanoma, a serious skin cancer. The vaccine was custom-made for each of the 15 participants using the unique genetic features of their own tumor. The main goals were to see if creating and giving this vaccine was safe…

This study tested a new treatment called lerapolturev, which is a modified polio virus, for people with advanced skin melanoma. The cancer in these patients had stopped responding to standard immunotherapy drugs (anti-PD-1). Researchers wanted to see if injecting the virus direct…

This early-stage study tested a new two-step stem cell transplant method for children and young adults whose cancers had returned or didn't respond to standard treatments. The goal was to see if this approach, which uses specially processed cells from a partially matched family d…

This study tested the safety and effectiveness of an experimental drug called BMS-986253 when given alongside established immunotherapy drugs (nivolumab with or without ipilimumab). It involved 281 people with advanced, hard-to-treat cancers, including melanoma. The main goals we…

This study tested the safety and effectiveness of a new drug, E7386, combined with an existing immunotherapy (pembrolizumab) for people with advanced melanoma, liver cancer, or colorectal cancer that had worsened after prior treatments. The first part checked for side effects and…

This large, completed Phase 3 trial tested if adding a new drug (vibostolimab) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone to prevent melanoma from coming back after surgery. It involved 1,594 people with high-risk melanoma who had their …

This early-phase study tested whether combining a short, intense course of radiation with two immunotherapy drugs is safe for patients with advanced cancers that have spread. The trial involved 53 adults with metastatic melanoma, lung, breast, or pancreatic cancer who had tried o…

This study tested whether injecting a new drug called BO-112 directly into tumors, along with the standard immunotherapy pembrolizumab, could help patients with advanced melanoma whose cancer had stopped responding to previous immunotherapy. The trial involved 42 adults with stag…

This study tested a combination of three immunotherapy drugs for people with advanced melanoma, a serious skin cancer. The main goals were to find safe doses and see if the treatment could shrink tumors, especially in patients whose cancer had stopped responding to standard immun…

This study tested a personalized approach for patients with advanced melanoma that had not responded to standard immunotherapy. Researchers analyzed the genetic makeup of each patient's tumor to find specific mutations. Patients were then given a targeted drug designed to attack …

This study tested if a new drug, ABP 206, behaves in the body similarly to an approved drug called nivolumab (OPDIVO®). It involved 256 adults with advanced melanoma that had been surgically removed, aiming to see if the new drug could be just as effective and safe at preventing …

This study tested whether a computer program using artificial intelligence (AI) could accurately identify melanoma, a serious type of skin cancer, from photos of skin spots. Researchers took pictures of suspicious spots from 105 adults using a special smartphone camera and compar…

This study tested new blood tests designed to detect cancer biomarkers in patients with recurrent or metastatic head & neck, lung, or skin cancer. The goal was to validate if these 'liquid biopsies' could accurately track cancer changes over time by analyzing genetic material in …

This study tested if giving a written advice sheet to melanoma patients, to pass to their close family members, would encourage more family members to get a skin check from a doctor. Family members of melanoma patients have a higher risk of getting it themselves, so early detecti…

This study tested a school-based program designed to prevent skin cancer in rural teenagers. About 38 students from Utah high schools participated in classroom lessons about sun safety and created personal protection plans. Researchers used surveys to see if the program changed s…

This study tested whether a 15-minute session of smelling lavender oil could reduce anxiety in adults about to have minor skin cancer surgery. 66 patients were randomly assigned to smell either lavender oil or a placebo scent before their procedure. Researchers measured anxiety l…

This study aimed to find biological signs that could predict if a patient's advanced melanoma would respond to immunotherapy drugs. Five patients had scans and tumor biopsies taken before and during their standard treatment. The goal was to learn how to better match patients with…

This study aimed to understand how the body's immune cells interact with melanoma tumors. Researchers analyzed tumor samples from 217 patients at different stages of the disease to see which immune cells were present and how they behaved. The goal was to learn why these cells som…

This study aims to understand when inflammation peaks in the body after starting a common type of cancer immunotherapy. Researchers measured markers in the blood of 98 adults with various cancers to see if these markers could predict side effects or interactions with other medica…

This research study aimed to understand how immune cells in the blood might predict whether melanoma patients respond to pembrolizumab immunotherapy. Researchers followed 25 patients with advanced melanoma who were starting standard pembrolizumab treatment. They analyzed blood sa…

This study aimed to understand how people with a close family member who had melanoma make decisions about sun protection. Researchers interviewed 94 participants about their sunscreen use, shade-seeking, hat wearing, and protective clothing choices. The goal was to learn what in…

This study looked back at the real-world experiences of 100 adults with stage III melanoma who received one of two combination drug treatments before surgery. Researchers collected information about the patients, their treatment details, side effects, and long-term outcomes like …

This study aimed to understand if melanoma skin cancer cells spread to nearby healthy-looking tissue very early in the disease. Researchers analyzed tissue samples from 226 patients with early-stage melanoma to look for hidden cancer cells. They wanted to see if finding these cel…

This study monitored melanoma patients who received the treatment IMLYGIC in real-world settings. Researchers followed 187 patients for up to five years to understand the risk of herpes infections from the treatment and whether those infections could spread to close contacts or h…

This study aimed to see if a simple blood test could help predict whether melanoma skin cancer might come back or get worse. Researchers followed 113 patients to check if tiny pieces of tumor DNA found in their blood were linked to their cancer's progression. The goal was to lear…